Theravance Biopharma Inc. (TBPH)
NASDAQ · Healthcare
Theravance Biopharma Inc. Long Term Debt 2012–2025
Theravance Biopharma Inc. annual long term debt history from 2017 to 2021. Long term debt refers to financial obligations that are due more than one year in the future.
- Theravance Biopharma Inc. long term debt as of December 31, 2021: 616.3M, a 0.46% decrease year-over-year.
- Theravance Biopharma Inc. long term debt for 2021 were 616.3M, a 0.46% decrease from 2020.
- Theravance Biopharma Inc. long term debt for 2020 were 619.2M, a 36.07% increase from 2019.
- Theravance Biopharma Inc. long term debt for 2019 were 455.0M, a 0.15% increase from 2018.
- Theravance Biopharma Inc. long term debt for 2018 were 454.4M.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Theravance Biopharma Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2021 | $616 |
| 2020 | $619 |
| 2019 | $455 |
| 2018 | $454 |
| 2017 | $224 |
Theravance Biopharma Inc. Long Term Debt — FAQ
Theravance Biopharma Inc. (TBPH) long term debt over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TBPH's long term debt history?
The chart and table above show Theravance Biopharma Inc.'s long term debt by year and by quarter, including the growth rate.